The gross margin expansion suggests a favorable mix shift toward higher-margin reconstructive implants, but the operating margin of 3.0% in 2026Q2 remains far below the 8.4% seen in 2025Q4, implying that SG&A and amortization continue to absorb gains. Net margin of -0.2% in 2026Q2, while improved from -90.4% in 2025Q4, still reflects the drag from non-cash charges and integration costs, suggesting the underlying earning power is not yet visible in GAAP figures. Investors should monitor whether operating leverage can sustain as revenue growth stabilizes, given the high fixed-cost base.

The improvement in ROIC from deeply negative levels suggests that the impairment charges and integration costs are abating, but a 0.5% return on invested capital is insufficient to cover the cost of capital, implying that the company is still in the early stages of recovering its return profile. ROE of -0.1% in 2026Q2, while dramatically better than -29.6% in 2025Q4, remains negative, reflecting the retained earnings deficit and the ongoing drag from amortization. The path to double-digit returns will require sustained margin expansion and efficient capital deployment, which has yet to be demonstrated.

The cash conversion cycle of 231 days is heavily influenced by days inventory outstanding of 245 days, which reflects the consignment inventory model common in orthopedics, but the trend is worsening from 214 days in 2024Q1, suggesting inventory management is becoming less efficient. DSO of 69 days is relatively stable, while DPO of 83 days provides some offset, but the net effect is a prolonged cycle that consumes cash. This may indicate that the company is holding excess inventory to support surgeon demand, but it also raises concerns about obsolescence risk and the need for working capital discipline.

The doubling of debt-to-equity from 0.43 to 0.93 reflects both the accumulation of debt and the erosion of equity due to cumulative losses, with retained earnings swinging to -$1.5B. Interest coverage of 1.93 in 2026Q2 is a marked improvement from negative levels in prior quarters, but it remains thin, suggesting that operating income barely covers interest expense. The D/EBITDA ratio of 15.47 is elevated, though this is distorted by depressed EBITDA; as margins recover, this ratio could improve, but the current level indicates limited headroom for additional debt.

The current ratio of 1.98 indicates that current assets cover current liabilities nearly twice over, but the sharp decline in cash to $12.6M raises concerns about the company's ability to absorb short-term shocks without drawing on credit lines. The quick ratio of 1.00 suggests that excluding inventory, the company barely covers its current liabilities, which is typical for a business with high inventory levels. Under a severe stress scenario, such as a drop in elective procedures, the thin cash buffer could force the company to rely on external financing, which may be constrained given the current leverage.